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Telomerecat: A ploidy-agnostic 
method for estimating telomere 
length from whole genome 
sequencing data
James H. R. Farmery1, Mike L. Smith2,  & NIHR BioResource - Rare Diseases*, Andy G. Lynch  1,3
Telomere length is a risk factor in disease and the dynamics of telomere length are crucial to our 
understanding of cell replication and vitality. The proliferation of whole genome sequencing 
represents an unprecedented opportunity to glean new insights into telomere biology on a previously 
unimaginable scale. To this end, a number of approaches for estimating telomere length from whole-
genome sequencing data have been proposed. Here we present Telomerecat, a novel approach to the 
estimation of telomere length. Previous methods have been dependent on the number of telomeres 
present in a cell being known, which may be problematic when analysing aneuploid cancer data and 
non-human samples. Telomerecat is designed to be agnostic to the number of telomeres present, 
making it suited for the purpose of estimating telomere length in cancer studies. Telomerecat also 
accounts for interstitial telomeric reads and presents a novel approach to dealing with sequencing 
errors. We show that Telomerecat performs well at telomere length estimation when compared to 
leading experimental and computational methods. Furthermore, we show that it detects expected 
patterns in longitudinal data, repeated measurements, and cross-species comparisons. We also apply 
the method to a cancer cell data, uncovering an interesting relationship with the underlying telomerase 
genotype.
Telomeres are the ribonucleoprotein structures that shield the ends of chromosomes from DNA damage 
responses1. They are multifunctional regions of the genome that, unless being actively lengthened (by e.g. telomer-
ase) will shorten with DNA duplication2. In this manner they both act as a molecular clock and provide a natural 
limit on the replicative potential of a cell, with possible pathways to apoptosis, senescence and, in cancer cells, 
genomic instability3. Telomere length is thus not only a risk factor for cancer and other diseases4, with germline 
mutations near to TERT (the gene encoding telomerase) being associated with several cancers5, but also has a 
mechanistic role in tumour aetiology through driving instability, influencing regulation of telomere-proximal 
genes6, and (through activation of telomere-lengthening) provision of replicative immortality7. In humans, the 
DNA component of telomere is an extremely repetitive region of the genome comprised of the nucleotide hex-
amer: (TTAGGG)n.
In this study we present Telomerecat, the first tool designed specifically to estimate mean telomere length 
from cancer whole genome sequencing (WGS) data. There have been previous approaches to using WGS data to 
say something about telomeres. Castle et al. provided a proof of concept in 20108, and this was refined by the first 
group to use such an approach in earnest9. Ding et al.10 published the first fully-fledged method for estimating 
length rather than just telomere content, with the accompanying tool ‘TelSeq’. Their study was also the first time a 
computational method had been validated against an established experimental method.
TelSeq assumes a fixed number of chromosomes when estimating telomere length and so makes no allowance 
for aneuploidy. Nevertheless, as the strongest available tool there are several examples of TelSeq being used to ana-
lyse cancer datasets11,12. Ṅotably a recent pan-cancer analysis made use of the TelSeq tool6. While generally sound, 
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such analyses are vulnerable to misinterpretation in the event of systematic differences in aneuploidy (as may be 
the case when comparing different cancer types). Indeed, recurrent somatic copy number alterations involving 
the telomere were observed in all cancer types studied in a pan-cancer study of Cancer Genome Atlas data13.
Where such changes (suggestive of aneuploidy) occur, cells will likely be left with an altered number of tel-
omeres. Accordingly the quantity (and proportion) of telomere sequence within the sample is altered, even if the 
mean length of telomeres is unaltered. Thus if we observe more telomere sequence in a cancer sample, we do not 
know if this is due to longer telomeres.
Two other tools of note have been published: Telomere Hunter and Computel. TelomereHunter14 reports 
telomere content rather than telomere length, and so does not provide a direct comparison. TelomereHunter 
classifies reads based on their mapping location within the parent BAM file and outputs statistics relating to 
variations of the canonic telomere hexamer. Computel15 does allow the user to specify the number of telomeres 
present, but since this is unknown (and cannot safely be inferred from copy-number profiles or ploidy statistics) 
it again does not provide a direct comparison. Since TelSeq is more frequently used in the literature, has greater 
experimental validation than Computel, and a recent comparison study16 did not find that the greater conveni-
ence of TelSeq was at the cost of poorer performance, we take TelSeq as the representative of current methods in 
our comparisons.
Rather than normalizing against the entire genome, Telomerecat normalizes the telomeric content against 
the subtelomeric regions. In this manner it is agnostic to the ploidy of the sample, and assumes only that each 
telomere has a subtelomere.
Erroneous regions of apparent telomere and subtelomere can arise from other stretches of the TTAGGG 
repeat sequence that appear in the human genome: so-called Interstitial telomeric repeats (‘ITRs’)17. Telomerecat 
estimates and corrects for the number of ITR-originating reads by assuming that the aggregate number of reads 
from the 3′ end of TTAGGG ITR sequences will be approximately equal to the aggregate number of reads from 
the 5′ end, while true telomeres only have a boundary at one end. In this manner, telomerecat obtains an estimate 
of ITR contributions without having to align to these difficult-to-map regions.
A third potential hindrance for telomere estimation, after aneuploidy and ITRs, is that it is difficult to define 
the end of the telomere precisely, based solely on genomic sequence (explicit information about DNA secondary 
structures and the locations of bound proteins having been lost). The subtelomere is composed of subtelomeric 
repeat sequences and segmental duplicates, interspersed by canonic telomere repeats18. These subtelomeric repeat 
sequences can look much like the telomere but with the addition of sequencing errors. Too strict a definition of 
telomere as being the region of TTAGGG repeats would be hostage to genuine variations, sequencing errors, and 
somatic mutations.
Telomere length is therefore necessarily a subjective measure, consistent only within the method used. 
Accordingly there may be an off-set in comparisons with other methods. Even ‘gold standard’ laboratory methods 
for measuring telomere lengths may have their own biases in this regard19.
Core to Telomerecat’s estimation process is the ratio between read-pairs that lie within the telomere and 
read-pairs that span the telomere boundary. Observing reads on the boundary between telomere and subtelomere 
provides a quantification of telomere numbers through which we normalize the telomere lengths. Where other 
samples always assume that more telomere reads mean longer telomere, Telomerecat is able to account for the fact 
that there may actually be more individual telomeres.
Moreover, differences in patterns of sequencing error have the potential to lead to inconsistency between 
samples even if using the same method. To this end, Telomerecat includes a novel method for correcting sequenc-
ing error in telomere sequencing reads. This model automatically adapts to differing error across sequencing 
preparations.
Telomerecat is an open source tool, the code is available from https://github.com/jhrf/telomerecat. Full instal-
lation and usage documentation is available at https://telomerecat.readthedocs.io.
Results
Validation in presumed-diploid blood samples. To verify that Telomerecat is able to identify telomere 
length within WGS samples, we compared the algorithm to an established experimental method (mean terminal 
restriction fragment Southern blot experiment (mTRF)) and the current leading computational method (TelSeq). 
Blood samples were taken from 260 adult females as part of the TwinsUK10K study, WGS and mTRF were con-
ducted on each sample (described previously20,21). The donor’s age at sample collection is also recorded for each 
sample. Since absolute agreement is not expected, we consider correlations between the methods. The results of 
the comparisons are shown in Table 1 and in Fig. 1.
We observe that the best correlation is between the the two computational methods at ρ = .0 631. The next 
best correlation was between mTRF and Telomerecat indicating that Telomerecat agrees with the established 
experimental method. Both Telomerecat and TelSeq correlate well with mTRF indicating that both tools are 
Telomerecat TelSeq mTRF
TelSeq ρ = 0.631 — —
mTRF ρ = 0.618 ρ = 0.583 —
Donor Age ρ = −0.306 ρ = −0.239 ρ = −0.321
Table 1. Results for the comparisons between Telomerecat, TelSeq, mTRF and Donor Age.
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providing realistic estimates of telomere length. The extent that Telomerecat correlates with mTRF is in line with 
correlations previously observed between other experimental methods and mTRF19.
Telomerecat estimates telomere length that is shorter, on average, than TelSeq. At least part of this disparity 
may be due to Telomerecat’s active filtering of reads from ITRs. Telomerecat finds that, on average 7% of telomeric 
read-pairs identified are from ITRs.
Telomerecat was able to identify a correlation with age only slightly weaker than that of mTRF, a strong indi-
cator that we are capturing genuine information about telomere lengths.
Application to a longitudinal MSC data set. We applied Telomerecat to a set of WGS samples from 
a mesenchymal stem cell (MSC) experiment described previously22. Mesenchymal stem cells are multipotent 
stromal cells commonly located in bone marrow23. The experiment constituted six WGS samples: an in vivo MSC 
sample from a healthy 31 year old male, three passaged MSC samples (P1,P8 and P13) and two induced pluripo-
tent stem cell (iPSC) samples.
MSCs are unusual amongst mature human stem cells as they do not express any measurable amount of 
telomerase24. Accordingly, telomere length attrition has been described in MSC passage experiments25,26. 
Conversely, iPSC cells have been shown to exhibit heightened telomerase expression27. We hypothesised that 
telomere length would shorten across the passaged MSC samples and lengthen within the iPSC samples.
The results of applying Telomerecat and TelSeq to the aforementioned MSC WGS data are shown in Fig. 2. 
Telomerecat identifies telomere shortening across the passaged samples, as expected. Telomerecat estimates that 
between P1 and P13 the average telomere length was shortened by 2.5 KB, at a rate of approximately 0.2KB per 
passage. Furthermore, we see that Telomerecat identifies long telomere length in the the two iPSC samples. We 
also note that TelSeq fails to identify the expected telomere dynamics. Possible explanations for this discrepancy 
are discussed in detail in the Supplementary Information Section 2.
Application to a cancer dataset. After establishing that Telomerecat performs well in diploid samples, 
we demonstrated that it can also be applied to cancer samples. We applied Telomerecat to a data set comprised of 
samples from four donors suffering from Hepatocellular carcinoma (HCC)28. Primary HCC cells were extracted 
from each donor in that study. These primary cells were cultured to create cell lines. Samples of the primary cells 
in vitro, an early passage and a late passage were taken for sequencing. Table 2 lists the exact passage number for 
each sample.
Figure 1. Scatter plots describing the relationship between Telomerecat, mTRF, and TelSeq estimates of 
telomere length (TL).
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Figure 3 shows the results of applying Telomerecat and TelSeq to the HCC cohort.
Telomerecat and TelSeq agree on CLC11 and CLC13 with both tools reporting only slight changes in telomere 
length across the passage experiment. However, the tools seem to diverge in their estimations for CLC16 and 
CLC5.
Telomerecat identified two telomere length phenotypes across the four donors. CLC11 and CLC13 show a tel-
omere length that is not altered across the passage process. By contrast, in CLC16 and CLC5 we see that telomere 
length increases across the passaged samples. Z. Qiu et. al report that all four samples contain corruptions in the 
TERT gene as shown in Table 2. It is interesting to note that CLC16 and CLC5 share both a TERT genotype and 
telomere length phenotype. Previous studies suggest that the presence of TERT promoter mutations and HBV 
Integration increases TERT expression29,30. However it is not clear that heightened expression is indicative of 
longer telomere lengths. Indeed, HCC tumours generally have shorter telomeres than adjacent normal cells31.
Although suggestive, further study and experimentation is required to ascertain the true nature between the 
underlying genotype and telomere length phenotype amongst cases of HCC.
Application to a set of repeated measurements. We have also tested Telomerecat on pairs of WGS 
repeated measurements from the NIHR BioResource - Rare Diseases study. Telomerecat was applied to 93 
samples of DNA extracted from whole blood. For each participant two samples were taken. Each sample was 
sequenced on either the HiSeq. 2000 or HiSeqX platform. We observe cases in this cohort where samples from 
the same participant were sequenced on the same technology and where samples were sequenced on different 
technologies. The blood samples from donor pairs were taken on separate occasions up to 3 years apart.
A sound approach to telomere-length estimation will be reproducible across duplicate samples. After account-
ing for batch effects relating to choice of platform, Telomerecat achieves good agreement between the repeat 
measurements, as shown in Fig. 4.
Figure 2. This figure shows estimates for the MSC samples produced by Telomerecat (left) and TelSeq (right). 
We expect to see a decrease in telomere length with additional passaging (P1 to P13), but consistent high 
telomere lengths in the two iPSC samples (iPSC1 and iPSC2).
CLC11 CLC13 CLC16 CLC5
Early Passage Count 6 3 3 7
Late Passage Count 24 18 21 27
TERT Promoter Mutation No Yes Yes Yes
TERT Amplification Yes Yes No No
HBV Integration Yes No No No
Table 2. Patients in the HCC study.
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We observe that estimates from the two measurements show a Pearson correlation of r = 0.8. We see that in 
80% of the duplicate pairs the difference in estimation is less than 1KB. Previous work suggests that the mTRF 
has a resolution of 1KB (although other methods have higher resolution)32. The fact that Telomerecat identifies 
displays a similar accuracy on a set of repeat measurements is a reassuring sign, especially given that we expect a 
certain amount of technical noise and true biological difference between the telomere length of these biological 
duplicates.
Figure 3. Telomerecat and TelSeq estimates for the HCC cell line dataset.
Figure 4. A plot of telomere length (TL) estimates for repeated measurement pairs. Colours correspond to the 
sequencing platform of each sample in the pair.
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Application to mouse samples. Mouse telomeres are known to be longer than human telomeres33. 
However, telomere length is known to vary across different mouse strains. We applied Telomerecat to 10 samples 
from the Mouse Genomes Project34.
Telomerecat identifies a range of telomere lengths, most of which are substantially greater than estimates from 
human samples. The estimates for the mouse samples, as well as two human samples for comparison, are shown 
in Fig. 5. TelSeq was not applied as the tool is specifically tailored to the human genome.
Telomerecat identifies a range of telomere lengths for the mice, almost all of the lengths are substantially 
longer than the longest human telomeres in the TwinsUK10K cohort. Additionally, we note that two of the 
samples with the shortest estimates - CAST Eij and SPRET Eij - have been identified as having comparatively 
short telomeres35–37. We also note that previous studies have identified the BALB cJ mouse strain as having long 
telomeres37.
A comparison of running time and resource allocation. Benchmarking was conducted on a MacPro 
desktop computer with 2 × 2.93 Ghz Quadcore Intel Xeon processors and 16GB of 1066Mhz DDR3 memory. The 
results of benchmarking for the Telomerecat and TelSeq tools can be found in Table 3. Benchmarking was con-
ducted on QTL190044 from the TwinsUK10K cohort. The results displayed are the average from the three runs.
Discussion
Here we have demonstrated and validated a novel approach to estimating telomere length from WGS data. 
Importantly, Telomerecat is the first tool designed to be applicable to cancer experiments as it does not assume a 
given number of telomeres.
We have validated Telomerecat by showing that it correlates with existing computational and experimental 
methods as well as with sample donor age. mTRF itself provides an imperfect measure of telomere length and, 
from correlations with age, it seems that computational methods may be capturing as much information as that 
approach. Specific wet-lab methods for estimating telomere length will likely remain the gold standard, but given 
the number of public initiatives generating large sets of sequencing data without matched telomere measure-
ments, improved methods for estimating telomere length from WGS data will always be desirable.
WGS-based methods will naturally become more accurate as the depth of sequencing increases. Much of the 
inaccuracy in the estimates of the TwinsUK10K data may be attributable to the relatively low coverage of those 
WGS data. At low coverage, Telomerecat’s estimate of the number of reads crossing the boundary is less certain. 
As coverage at the boundary decreases and the observed read counts for each individual sample become less 
Figure 5. Telomere length estimates by Telomerecat for 10 mouse samples from the Mouse Genomes Project.
Telomerecat TelSeq
Time Taken (seconds) 756 3894
Reads per hour 1.562 × 109 3.299 × 108
Max. Processor Usage (%) 537.6 96.8
Avg. Processor Usage (%) 356.8 80
Max. Memory Usage (GB) 1.9 0.104
Avg. Memory Usage (GB) 1.3 0.037
Table 3. Benchmarking results for Telomerecat and TelSeq.
www.nature.com/scientificreports/
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certain Telomerecat relies more on the cohort error adjustment (discussed in the methods section). With higher 
coverage we would expect even better agreement between Telomerecat and the other methods for diploid cells.
We have demonstrated here that Telomerecat is capable of producing estimates that are at least as accurate as 
computational methods that make an assumption about the number of chromosomes or telomeres, when applied 
to samples which are presumed to meet this assumption. When the assumption of number of telomeres doesn’t 
hold, it is reasonable to assume that Telomerecat will still do at least as well, and most likely will do better, as the 
other methods must see a drop off in accuracy through making such an assumption erroneously. In Section 2 of 
Supplementary Information we show through simulated data that Telomerecat is not biased by the true chromo-
some count. There are limited gold standard data available to demonstrate the advantages empirically, but if two 
well-matched methods differ in their estimates for a particular case, and the first makes an assumption that for 
that case is demonstrably wrong, it is logical to give credence to the second.
By applying Telomerecat to the duplicate blood samples we have demonstrated Telomerecat’s ability to gener-
ate meaningful results on two of the most popular Illumina paired-end platforms. As well as confirming the reli-
ability of Telomerecat’s telomere length estimates, this shows that the estimates are robust to sequencing batches 
once batch effects are accounted for.
Amongst the most striking results presented here is the estimation of telomere length across MSC cell line 
passaged data. Telomerecat identifies a clear deterioration of telomere length across the passaged cells and an 
increase of telomere length in the iPSC samples, in which telomerase had been reactivated. TelSeq fails to identify 
this pattern.
We see that the most likely reason for TelSeq’s failure to observe the expected telomere dynamics is in the 
GC correction part of the algorithm (see Section 2 of Supplementary Information for more detailed analysis). 
This indicates that the relationship between coverage at locations where genomic GC is identical to telomere and 
actual telomere, on which TelSeq relies, may not always be consistent across experiments.
We have presented the first application of a WGS telomere length estimation approach to data derived from 
non human samples; Telomerecat’s agnosticism to telomere numbers provides a natural advantage here also. As 
expected, Telomerecat identifies long telomere length in most of the mice samples. Pleasingly, Telomerecat is 
concordant with the literature in demonstrating the short telomeres in CAST EiJ and SPRET cJ samples and long 
telomeres in BALB cJ.
Telomerecat tends to report shorter telomere length than other methods, both computational and experi-
mental. There will be several contributing factors, including disagreement over the definition of the telomere/
sub-telomere boundary, and the stringency for categorizing read-pairs as being telomeric. One clear contributing 
factor in the comparison of computational methods will be Telomerecat’s exclusion of ITR read-pairs, typically 
contributing 4% to 10% of apparently telomeric read-pairs.
We have also demonstrated that Telomerecat can be run quickly (five times faster than TelSeq for our exam-
ple). Telomerecat is able to process samples quickly as it is built on a parallel BAM processing framework - para-
bam38 - and thus uses multiple processing cores at all stages of the analysis. Telomerecat promotes reproducible 
research by generating subsets of reads from which telomere length estimates can be generated. We hope that 
these smaller file will be more easily stored and transferred allowing researchers to regenerate estimates without 
the need to process the cumbersome original BAM files.
Finally, we have demonstrated the application to a cancer WGS dataset: Telomerecat’s raison d’être. We see 
that Telomerecat identifies differing telomere phenotypes across four passage experiments. Intriguingly the two 
experiments with the most similar telomere length phenotype have an identical underlying TERT corruption.
Methods
Overview. Telomerecat functions as three discrete operations: TELBAM generation, read categorisation and 
length estimation. A flowchart depicting the method is given in Fig. 6.
First, we collect a relevant subset of reads and their pairs from a BAM file. This subset is referred to as a 
TELBAM and consists of read pairs where one end of a read pair has two occurrences of the telomeric hexamer. 
This read subsetting operation is expedited by using the parallel processing framework parabam38. We observe 
that TELBAMs contain less than one ten-thousandth of the reads from an input BAM file.
Next we categorise read pairs according to their sequence composition and orientation on the genome. The 
telomere length estimate is informed by a ratio of complete telomere read pairs to read pairs on the boundary 
between telomere and subtelomere. In order to differentiate between the various type of telomere read we must 
first understand how reads differ from the telomere sequence and whether these differences are genuine biological 
perturbations or the result of sequencing error.
Lastly, we use the ratio of complete to boundary read-pairs in conjunction with insert length distribution to 
estimate the underlying telomere length that produced the observed complete to boundary ratio.
Defining error in telomere reads. Key to the process of identifying sequencing error is identifying loci 
within reads that do not match the expected telomere sequence. We shall refer to these as “mismatching loci”. 
Telomeres are extremely repetitive stretches of DNA. This repetition of sequence allows us to imagine a hypothet-
ical telomere sequence and then to compare reads to the hypothetical sequence to find differences. In order to 
account for insertions and deletions in the sequencing reads (both biological and as a result of sequencing error) 
we use a method of fragmentary local alignment. Reads that suffer few mismatches, and those mismatches at loci 
with low Phred scores, likely represent complete telomere sequences.
Since mismatch loci that represent sequencing errors should be associated with lower Phred scores, we first 
observe the empirical joint distribution of Phred scores at mismatching loci (as determined by the algorithm 
shown in Fig. 7), and number of mismatching loci across the BAM file (Fig. 8A) before constructing the equiv-
alent distribution for loci chosen at random within the reads (Fig. 8B). We find that reads with few mismatches 
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and low Phred scores (complete telomere sequences suffering from sequencing error) are over-represented in the 
empirical data set.
We define Pmax and Pmin as the global maximum and minimum observed Phred score across all reads, and (L) 
as the read length used.
We let N represent the total number of reads in the TELBAM such that ... −n N{0, 1, , , 1} are indices repre-
senting each read. Values associated with the nth read are denoted with a superscript (n). For example, the vector 
of Phred scores associated with the L locations in read n is denoted = ... −p p pp { , , , }
n n n
L
n( )
0
( )
1
( )
1
( ) . For the nth read, 
let m n( ) be a random vector in the space {0, 1}L such that a 1 is found at each loci in the read that does not agree 
with the telomere sequence. In the case that the sequence is comprised of perfect telomere sequence then the 
vector should sum to zero. The method for obtaining m n( ) via an fragmentary alignment method is shown in 
Fig. 7.
Then define zn (the number of mismatches for read n), and λn (the average Phred score at mismatches in read 
n) as:
∑
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=
⎢
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We then define an indicator function
λ
λ
λ
=
⎧
⎨
⎪⎪
⎩⎪⎪
= ∧ =
≠ ∨ ≠ .
z i j i z ji z j1( , , , ) :
1 if ,
0 if (2)
So that a matrix X takes the form,
∑ λ=
=
−
x z i j1( , , , )
(3)
ij
n
N
n n
0
1
( ) ( )
Where ∈ ... −i P P{0, , }max min  and ∈ ... −j L{0, , 1}. Thus each xij in X records the number of reads with the 
relevant λ and z contained within the TELBAM and is depicted in Fig. 8A.
Where X captures information about the average Phred score (λ n( )) at z n( ) mismatching loci, we seek to create 
an equivalent matrix Y about the average Phred score at z n( ) random loci in the nth read.
For the nth read, let r n( ) be a random vector in the space {0,1}L such that ∑ == r zkL k
n n
1
( ) ( ). That is, a vector for 
which the non-zero entries identify z n( ) random loci within the read.
So that,
µ =
⎢
⎣
⎢
⎢
⎢
∑ ⎥
⎦
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⎥
⎥
−=
z
P
r p
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Thus,
Figure 6. An overview of the Telomerecat length estimation process.
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∑
µ
µ
µ
µ
=
⎧
⎨
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⎩⎪⎪
= ∧ =
≠ ∨ ≠ .
=
=
−
z i j i z ji z j
y z i j
1( , , , ) : 1 if ,
0 if
1( , , , )
(5)ij n
N
n n
0
1
( ) ( )
As before, ∈ ... −i P P{0, , }max min  and j ∈ ... −L{0, , 1}.
When we plot the matrices X (Fig. 8A) and Y (Fig. 8B) as heat maps we typically see that there is a striking 
difference in their composition. The heatmap for X shows an intensity in the upper left hand corner pertaining to 
Figure 7. The algorithm that determines the indices of divergence from the telomere sequence. 0: We observe 
a sequencing read 1: We split the read into ‘segments’ (11 in total in our example) such that each segment is a 
substring of the original sequence and that every other segment consists of unbroken telomere sequence. In our 
example we see that segments 1,3,5,7,9,11 contain unbroken telomere sequence. 2: Each segment containing a 
telomere hexamer is ‘expanded‘ to capture the full extent of the surrounding telomere sequence. The number of 
segments is reduced by 2. 3: When two segments both containing the telomere hexamer are adjacent after Step 
2 this indicates a deletion event. We take the loci with the lowest corresponding Phred score. For any segment 
that does not contain a telomere hexamer and where the length of the segment is greater or equal to 4 apply we 
conduct a basic alignment of all possible telomere offset telomere sequences. The telomere sequence with the 
lowest Hamming distance is taken as a local alignment for that segment. Where two alignments are equal the 
one with the lowest average Phred score is preferred. 4: Sequence loci that are not in a complete hexamer or 
were mismatched in the Hamming alignment step are taken as mismatching loci. m for this example is given in 
the final line of the diagram.
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reads with low Phred scores at mismatching loci. This hotspot is missing from the Y heatmap. We interpret this 
region as representing telomere reads affected by sequencing error that we wish to capture in our length estima-
tion process.
We find the difference between the two matrices:
= −D X Y (6)
We plot values of D > 0 as a heatmap in 8C. To capture cells that contain more reads than we would expect at 
random we define a mask E. E is defined such that:
=
⎛
⎝
⎜⎜⎜⎜
>
≤ .
e
d k
d k
1 if ,
0 if (7)
ij
ij
ij
Where k is max D{ }ij  for all values where < ≤p i p
1
2
 and < ≤L j L12 . This matrix is depicted as a heatmap in Fig. 8D.
Figure 8. (A) A heatmap of the joint distribution of Phred scores a mismatching loci and the number of 
mismatching loci (X). The intensities in the top left corner of the heatmap indicate an association between fewer 
mismatches and lower phred scores. We observe that the maximum mismatching loci is commonly ~75% of 
the read length. This effect is caused by non-telomere reads match a the telomere sequence simply by chance 
(B) A heatmap of the joint distribution of random loci in reads and the associated phred score (Y). We note that 
the joint distirubtion of reads in the upper half of the matrix is different to that in X while the lower portion is 
identical. (C) The difference between X and Y. Referred to as D in the text. (D) A binary heatmap showing all cells 
in D that are greater than the threshold k. We note the preponderance of cells in the upper left hand corner of the 
figure (E) We remove noise from the figure using the methods detailed in (Supplementary Algorithm 1) (F) We 
apply a final rule to ensure cells associated with low Phred scores are captured in the error profile (Supplementary 
Algorithm 2).
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We note that the mask depicted in Fig. 8D has gaps that appear as a result of using k as a threshold. We 
apply the procedure detailed in Supplementary Algorithm 1 in order to remove noise from the error profile. 
The results of applying this procedure are shown in Fig. 8E. We conclude by applying the operation described in 
Supplementary Algorithm 2 and shown in Fig. 8F. This is the final matrix and is provided to the read classification 
procedure shown in Supplementary Algorithm 3 as E. All reads falling within the area by the error profile are 
counted as fully telomeric suffering from sequencing error.
Our definitive definition of a fully telomeric read is a read where 90% of the the sequence is telomere or the 
read falls into the error profile (See Supplementary Algorithm 3). In practice we observe that using a threshold 
above 90% leads to decreased accuracy. It is possible that this is indicative of genuine telomere heterogeneity but 
further study is required to understand this phenomenon.
Categorising telomere read types. Once we have adequately described sequencing error we now classify 
each read-pair. In this section we describe the step that allows us to sort read-pairs into ‘complete’ read-pairs 
(denoted F1 reads in Fig. 9 - both reads of the pair lying wholly within the telomere) and boundary (F2a - exactly 
one read of the pair lying wholly within the telomere) reads.
The Telomerecat length estimation method requires that all read pairs are sorted into four categories: F1, 
F2, F3 F4. Examples of each read type are given in Fig. 9. Pseudocode for categorisation of reads is given in 
Supplementary Algorithm 3.
The read categorisation process is crucial to Telomerecat’s ability to filter interstitial reads. As we see in Fig. 9, 
the F2 category contains read pairs where one end consists of the canonical CCCTAA telomeric repeat and the 
other does not. Read pairs that meet this criteria can be found both at the boundary between the telomere and the 
Figure 9. (A) The read-pair types at the boundary between telomere and subtelomere. F2a reads stem from 
the boundary whereas F1 reads stem from anywhere within the telomere proper. F3 are reads where neither 
read in the pair is complete telomere (B) Detail of the F1 and F2a read types. F1 read-pairs are comprised of 
two complete telomere reads. F2a read-pairs are comprised of a read-pair where one read is complete telomere 
and the other is not. Crucially, the complete telomere read is comprised of CCCTAA (C) The read-pair types 
at an ITR. (D) Detail of the F2b and F4 read types. Note that the F2b is physical indistinguishable from an F2a 
read. An F4 read is read-pair where one read is complete telomere and the other is not. The complete end is 
comprised of TTAGGG.
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rest of the genome, and on one side of an ITR. We refer to these two distinct cases as F2a and F2b, but we cannot 
directly observe the number of F2a or F2b read pairs; the orientation and sequence content of the read types are 
identical. However, the directional nature of WGS allows us to identify read pairs spanning the other boundary 
between an ITR and the genome. For such read pairs the telomere-like end will be read as TTAGGG, allowing us 
to easily distinguish them. We categorise these as F4 read pairs in Fig. 9. Read pairs in this category should only 
be found at ITR boundaries, as the chromosome does not continue beyond truly telomeric read pairs. We can 
use this fact, combined with the observation that on average, within a sequencing experiment, there should be a 
corresponding F2b for each F4, to deduce the amount of F2a reads. So it follows that.
≡
= −
F b F
F a F F b
2 4
2 2 2 (8)
F4 reads give us an estimate of ITR reads, so subtracting F4 from F2 we are left with a count of reads F2 for which 
there was no corresponding F4. We posit that this is the count of reads on the boundary between telomere and 
subtelomere.
This method allows us to attain an estimate of F2a without filtering reads based on any upstream process-
ing or any sequence structure beyond a distinction between “complete” and “incomplete” (see Supplementary 
Algorithm 3).
Using cohort wide information to correct error in F2a counts. We observe that in some cases it is 
useful to normalise a cohort’s F2a count based on information from other samples in the batch. What follows is a 
method for adjusting F2a using a weighted average.
Let C be the total number of TELBAMs in a batch provided to Telomerecat. Such that subscript c represents a 
value relevant to any individual TELBAM. Let θ =
+
F a
F F
2
2 4
 such that θexp is the average θ observed across all 
TELBAMs in a cohort and θcobs is the observed value of θ with in a particular TELBAM.
θ
θ
θ
θ ψ θ
ψ
= ∑
=
⋅ + ⋅
⋅
=
C
w
w (9)
exp c
C
c
obs
c
cor c
obs
c
exp
c
1
Where w is a predetermined weight of 3. ψ for any given TELBAM is obtained as follows.
µ
σ
µ
ψ
σ
µ
=
∑ ∑
⋅
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⋅
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So it follows that the adjusted value of F2a is given as θ ⋅ +F F( 2 4)cor .
Estimating length from read pair categories. The final step of the telomere length estimation process 
involves converting a ratio of F1:F2a read counts into an estimation of length. We achieve this by simulating tel-
omere length under the observation of counts for F1, F2a and the fragment size. Psuedocode for the simulation 
is given in Algorithm 1.
Batch effect correction when multiple sequencing platforms are used. Our observation has been 
that estimates from the HiSeqX platform are shorter on average than estimates from the HiSeq. 2000 platform. We 
have also observed that samples sequenced on the HiSeqX platform show lower scores in quality assessment. To 
account for this effect we propose that a mean correction should be applied to estimates from the HiSeqX platform.
Algorithm 1. Telomerecat length estimation simulation algorithm.
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Data Availability. 
 1. The Twins UK10K sequencing data are available from the EGA repository (accession ID: 
EGAD00001000194) but restrictions apply to the availability of these data, which were used under license 
for the current study, and so are not publicly available. Data are however available upon reasonable request 
to datasharing@sanger.ac.uk and with permission of Twins UK10K.
 2. The MSC sequencing datasets analysed during the current study are available in the NCBI SRA repository 
under accession ID SRP032359, https://www.ncbi.nlm.nih.gov/sra/?term=SRP032359.
 3. The HCC sequencing sequencing data are available from the EGA repository (accession ID: 
EGAD00001001995) but restrictions apply to the availability of these data, which were used under license 
for the current study, and so are not publicly available. Data are however available upon reasonable request 
to qiuzhixin@sibcb.ac.cn.
 4. The repeated measurement sequencing data are available from the EGA repository (accession ID: 
EGAD00001003809) but restrictions apply to the availability of these data, which were used under license 
for the current study, and so are not publicly available. Data are however available upon reasonable request to 
Kathleen Stirrups (nihr_dac@medschl.cam.ac.uk) and with permission of NIHR BioResource - Rare Diseases.
 5. The mice sequencing datasets analysed during the current study are available from the mouse genome 
project website repository, http://www.sanger.ac.uk/science/data/mouse-genomes-project.
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